Chronic rejection of transplanted hearts

Current Opinion in Organ Transplantation

Volumn 6, Issue 3, 2001, Pages 205-210

  Yun, James J ^a   Fischbein, Michael P ^a   Laks, Hillel ^a   Ardehali, Abbas ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PRAVASTATIN;

ARTICLE; CHRONIC DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DISEASE COURSE; GRAFT FAILURE; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; IMMUNE SYSTEM; INTRAVASCULAR ULTRASOUND; ISCHEMIC HEART DISEASE; LASER SURGERY; MEDICAL ETHICS; MEDICAL RESEARCH; ORGAN DONOR; POSTOPERATIVE PERIOD; RECIPIENT; RECURRENT DISEASE; REOPERATION; SUDDEN DEATH; TREATMENT OUTCOME;

EID: 0035700171     PISSN: 10872418     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075200-200109000-00001     Document Type: Article

References (83)

1. The Registry of the International Society for Heart Lung Transplantation: Seventeenth official report-2000 2000
2. Worldwide thoracic organ transplantation: A report from the UNOS/ISHLT international registry for thoracic organ transplantation
3. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone
4. Heart transplant coronary artery disease detected by coronary angiography: A multi-institutional study of pre-operative donor and recipient risk factors
5. Incidence, progression and functional significance of cardiac allograft vasculopathy after heart transplantation
6. Transplant coronary artery disease in pediatric heart transplant recipients
7. Pediatric cardiac retransplantation: Intermediate-term results
8. Heart transplantation among 233 infants during the first six months of life: The Loma Linda experience
9. Cardiac transplantation in man. VII. Cardiac allograft pathology
10. Pathology of graft vascular disease after heart and heart-lung transplantation and its relation to obliterative bronchiolitis
11. Histopathology of graft coronary disease
12. Human coronary transplantation-associated arteriosclerosis. Evidence for a chronic immune reaction to activated graft endothelial cells
13. Atherosclerosis-an inflammatory disease
14. Production of severe atheroma in a transplanted human heart
15. Myocardial changes in cardiac transplant-associated coronary arteriosclerosis: Ppotential for timely diagnosis
16. Quantitative investigation of cardiomyocyte hypertrophy and myocardial fibrosis over 6 years after cardiac transplantation
17. Longitudinal study of vascular remodeling in coronary arteries after heart transplantation
18. Cardiac allograft vasculopathy: The central pathogenetic role of ischemia-induced endothelial cell injury
19. Immune and nonimmune mechanisms of chronic rejection of kidney allografts
20. Syndromes of accelerated atherosclerosis: Role of vascular injury and smooth muscle cell proliferation
21. Vascular cell adhesion molecule-1 is induced on vascular endothelia and medial smooth muscle cells in experimental cardiac allograft vasculopathy
22. Immunopathology of cardiac transplant rejection
23. Cardiac allograft vasculopathy
24. Transplantation-associated arteriosclerosis: Potential mechanisms
25. Brain death and its impact on the donor heart-lessons from animal models
26. The influence of donor brain death on long-term function of renal allotransplants in rats
27. Expression of major histocompatibility antigens and vascular adhesion molecules on human cardiac allografts preserved in University of Wisconsin solution
28. University of Wisconsin solution versus Stanford cardioplegic solution and the development of cardiac allograft vasculopathy
29. Loss of endothelium-dependent vasodilatation and nitric oxide release after myocardial protection with University of Wisconsin solution
30. Ischemia/reperfusion injury in transplantation
31. Sustained anti-CD4/CD8 treatment blocks inflammatory activation and intimal thickening in mouse heart allografts
32. CD8+ lymphocytes augment chronic rejection in an MHC class II mismatched model
33. Cardiac allograft vasculopathy is abrogated by anti-CD8 monoclonal antibody therapy
34. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes
35. Acute rejection and coronary artery disease in long-term survivors of heart transplantation
36. Late rejection is a predictor of transplant coronary artery disease in children
37. Graft arteriosclerosis: Molecular features of macrophage activation
38. Allograft inflammatory factory-1. A cytokine-responsive macrophage molecule expressed in transplanted human hearts
39. Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity
40. Relation of HLA antibodies and graft atherosclerosis in human cardiac allograft recipients
41. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
42. Chronic blockade of CD28-B7-mediated T-cell costimulation by CTLA4Ig reduces intimal thickening in MHC class I and II incompatible mouse heart allografts
43. CD40 signaling replaces CD4+ lymphocytes and its blocking prevents chronic rejection of heart transplants 2000
44. Analysis of CD154 and CD40 expression in native coronary atherosclerosis and transplant associated coronary artery disease
45. Dancing to the tune of chemokines
46. RANTES chemokine expression in transplant-associated accelerated atherosclerosis
47. RANTES production during development of cardiac allograft vasculopathy
48. Early and late chemokine production correlates with cellular recruitment in cardiac allograft vasculopathy
49. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection
50. Transplant coronary disease: Nonimmunologic risk factors
51. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis
52. CMV and transplant-related coronary atherosclerosis: An immunohistochemical, in hybridization, and polymerase chain reaction in situ study
53. The impact of cyclosporine dose and level on the development and progression of allograft coronary disease
54. Transforming growth factor beta in relation to cardiac allograft vasculopathy after heart transplantation
55. ACE-gene polymorphism is associated with the development of allograft vascular disease in heart transplant recipients
56. Gene polymorphisms for plasminogen activator inhibitor-1/tissue plasminogen activator and development of allograft coronary artery disease
57. Identification of ICAM-1 polymorphism that is associated with protection from associated vasculopathy after cardiac transplantation
58. Vagal reinnervation in the long term after orthotopic heart transplantation
59. Heart transplantation: Accelerated graft atherosclerosis
60. Insensitivity of noninvasive tests to detect coronary artery vasculopathy after heart transplant
61. Dobutamine technetium-99m tetrofosmin SPECT imaging for the diagnosis of coronary artery disease in patients with limited exercise capacity
62. Diagnostic and prognostic value of serial dobutamine stress echocardiography for noninvasive assessment of cardiac allograft vasculopathy: A comparison with coronary angiography and intravascular ultrasound
63. Dobutamine stress echocardiography: Experience in pediatric heart transplant recipients
64. Electron-beam computed tomography in the assessment of coronary artery disease after heart transplantation
65. Necropsy versus angiography: How accurate is angiography?
66. Coronary angiography after heart transplantation: Should perioperative study be the 'gold standard?'
67. Intravascular ultrasound for assessment of coronary allograft vasculopathy
68. Determinants of coronary remodeling in transplant coronary disease: A simultaneous intravascular ultrasound and Doppler flow study
69. Effect of pravastatin on outcomes after cardiac transplantation
70. Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomized trial
71. What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?
72. An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy
73. Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients
74. Angiographic and clinical follow-up of percutaneous revascularization for transplant coronary artery disease
75. Coronary angioplasty and stenting in orthotopic heart transplants: A fruitful act or a futile attempt?
76. Coronary angioplasty and stenting in cardiac allograft vasculopathy following heart transplantation
77. Thoracic and cardiovascular interventions after orthotopic heart transplantation
78. Cardiac allograft vasculopathy-coronary interventions and surgical options
79. Coronary interventional procedures in pediatric heart transplant recipients with cardiac allograft vasculopathy
80. 2 laser in patients with refractory angina pectoris. Clinical results from the Norwegian randomized trial
81. Long-term outcome of cardiac allograft vasculopathy treated by transmyocardial laser revascularization: Early rewards, late losses
82. The results of cardiac retransplantation: An analysis of the Joint International Society for Heart Lung Transplantation/United Network for Organ Sharing Thoracic Registry
83. The University of California at Los Angeles experience in heart transplantation